Insmed Announces Upcoming Data Presentations at ERS 2015
22 Septembre 2015 - 2:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the needs of patients with rare diseases today
reported two ARIKAYCE™ (liposomal amikacin for inhalation) posters
will be presented at the European Respiratory Society (ERS)
International Congress taking place in Amsterdam from September
26-30.
Summarized below are the poster titles and presentation
times.
Poster Title: Amikacin (AMK) minimum inhibitory
concentrations (MICs) and mutational resistance in patients with
treatment-refractory nontuberculous mycobacteria (NTM) lung disease
(LD) treated with liposomal amikacin for inhalation (LAI)
Lead Author: K. Olivier Poster
Number: PA371Date: Sunday, September 27,
2015Session Time: 08:30-10:30 AMSession
Title: Bronchiectasis and NTM infections: clinical aspects
and research outlook
Poster Title: A randomized, open-label,
multicenter study of liposomal amikacin for inhalation in adult
patients with nontuberculous mycobacteria (NTM) lung infections
caused by mycobacterium avium complex (MAC)
Lead Author: D. GriffithPoster
Number: PA3945Date: Tuesday, September
29, 2015Session Time: 12:50 PM-2:40 PM
Session Title: Novel strategies for the management
of asthma, COPD and airway infections
Additional information about ERS 2015 can be found on the
congress website at http://erscongress.org/. The posters will be
made available on the Insmed’s website after presentation at the
meeting.
About Insmed
Insmed Incorporated is a global
biopharmaceutical company focused on the needs of patients with
rare diseases. The company is advancing a global phase 3 clinical
study of ARIKAYCE™ (liposomal amikacin for inhalation) in
nontuberculous mycobacteria (NTM) lung disease, a rare and often
chronic infection that can lead to progressive inflammation and
lung damage. There are no currently approved treatments for NTM in
the United States or European Union (EU). In the EU, the
company has filed a marketing authorization application seeking
approval of ARIKAYCE for use in patients with NTM, as well as in
cystic fibrosis patients with Pseudomonas aeruginosa lung
infections. Insmed’s earlier-stage pipeline includes INS1009, a
nebulized prodrug formulation of treprostinil that the company is
developing for the treatment of pulmonary arterial hypertension
(PAH), a chronic, life-threatening disorder characterized by
abnormally high blood pressure in the arteries between the heart
and lungs. To complement its internal research, Insmed actively
seeks in-licensing opportunities for a broad range of rare
diseases. For more information visit www.insmed.com.
Insmed Incorporated:
Susan Mesco
Head of Investor Relations
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024